OR WAIT null SECS
September 06, 2026
Article
The oral RARβ/γ agonist improved FVC and reduced fibrotic biomarkers over 12 weeks in a phase 2a trial presented at the ERS Congress 2026.
September 04, 2026
August 2026 pulmonology highlights include deupirfenidone's positive phase 2b ELEVATE-IPF results, FDA Fast Track for LTI-03, and more.
September 03, 2026
The FDA is expected to complete its review by late April 2027, based on positive phase 3 results from the TETON-1 and TETON-2 trials in IPF.
August 22, 2026
Video
One year after FDA approval, Mark Metersky, MD, discusses which bronchiectasis patients benefit most from brensocatib and its safety profile.
August 21, 2026
Pamufetinib 50 mg and 100 mg did not slow FVC decline versus continued nintedanib or pirfenidone in progressive fibrosing ILD, a phase 2b trial found.
August 20, 2026
Deupirfenidone 825 mg reduced 26-week FVC decline by 91.0 mL versus placebo in the phase 2b ELEVATE-IPF trial in idiopathic pulmonary fibrosis.
The Fast Track designation adds to LTI-03's prior Orphan Drug status as Rein Therapeutics advances the Phase 2 RENEW trial in IPF.
August 04, 2026
Highlights include an exploratory nerandomilast mortality analysis, the first North American bronchiectasis guideline from CHEST, and more.
July 31, 2026
Pooled FIBRONEER trial data show nerandomilast reduced the risk of death by up to 43% versus placebo, though the analysis was post hoc.
John Giacona, PhD, PA-C, discusses building a comprehensive multidisciplinary care team for interstitial lung disease and how APPs should engage with clinical evidence.
